Epilepsy. Episodic and paroxysmal disorders
Conditions
Interventions
Intervention 1: oral melatonin 0.3 mg/kg/dose. Intervention 2: oral midazolam 0.75mg/kg/dose.
oral melatonin 0.3 mg/kg/dose
oral midazolam 0.75mg/kg/dose
Sponsors
Deputy of research -Shahid Sadoughi University of Medical Sciences , Yazd, Iran
Eligibility
Sex/Gender
All
Age
1 Years to 10 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age 1-18 years old; children who are referred to EEG center but don’t obey, , class 1 or 2 of ASA Exclusion criteria: Presence of gastritis or any other serious systemic diseases, use of sedative in two days ago ; occurrence of severe systemic reaction wth drugs
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sedation induction with achieving of a level of four on the Ramsay scale. Timepoint: every 15 minutes. Method of measurement: clinical.;Success in recording of EEG. Timepoint: one hour after drug use. Method of measurement: clinical. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serious adverse events (hypotension, hypoxia and cyanosis, severe vomiting, irritability, apnea, laryngospasm, and bradycardia). Timepoint: every 10 minutes. Method of measurement: clinical.;Side effects. Timepoint: every 15 minutes. Method of measurement: clinical.;Time to induction of sedation. Timepoint: every 15 minutes. Method of measurement: clinical.;Caregiver’s satisfaction scale. Timepoint: after 2 hours of drug use. Method of measurement: asking from caregiver.;Total stay time in EEG unit. Timepoint: every 30 minutes. Method of measurement: asking from parents. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed